Cracking Down on Harmful Drug Combinations | 01 October, 2025

Yet, irrational or harmful fixed-dose combinations (FDCs) have long undermined these goals, posing significant risks through side effects, misuse, and drug dependency. Maharashtra’s Food and Drug Administration (FDA) is taking decisive action to eliminate such hazardous formulations from the market, reinforcing its commitment to public health.

Understanding the Problem FDCs combine two or more active pharmaceutical ingredients into a single preparation. While some offer therapeutic benefits and improve treatment adherence, others lack scientific justification or present heightened safety risks. Dangerous examples include narcotic and psychotropic substances blended unlawfully—such as the potent painkiller Tapentadol mixed with muscle relaxant Carisoprodol—raising serious concerns about abuse and adverse effects.

To address these threats, the Maharashtra FDA has launched a multi-pronged inspection and enforcement drive: Market Surveillance: Teams carry out routine and surprise inspections at manufacturing sites, wholesale distributors, pharmacies, and retailers to detect harmful combinations. Suspect products are seized and sent for laboratory testing.

Licensing Controls: Manufacturers producing banned or unapproved FDCs face suspension or cancellation of licences, halting production. Retailers found stocking such products are penalised, with fines and potential licence revocations. Recall Operations: Harmful formulations already in circulation are traced and withdrawn from the market to prevent further exposure. This swift response removes unsafe medicines and sends a strong deterrent signal to manufacturers tempted to compromise on safety.

Raising Awareness Recognising that regulation alone cannot eradicate misuse, the FDA is expanding its efforts to educate healthcare providers. Training programmes are being planned to update doctors, pharmacists, and other medical professionals on banned combinations, safer alternatives, and rational prescribing practices.

Public advisories will complement these measures, encouraging patients to check prescriptions carefully and question the safety of medicines. Empowering both prescribers and consumers creates a stronger defence against irrational drug use.

The crackdown aligns with national policies under the Drugs Controller General of India, which has prohibited numerous irrational FDCs. Maharashtra’s robust enforcement ensures rapid compliance, avoiding dangerous delays in implementation. Globally, regulators emphasise vigilant pharmacovigilance and post-marketing surveillance—areas where Maharashtra is investing in laboratory infrastructure and digital monitoring to strengthen oversight.

Towards Safer Medicines By eliminating harmful drug combinations, the Maharashtra FDA is reducing avoidable medical risks, promoting evidence-based prescribing, and restoring confidence in the healthcare system. The long-term impact will be felt not only in improved patient safety but also in encouraging pharmaceutical innovation rooted in scientific integrity rather than expediency.

(Source: Business Standard)